Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study

Capsule Summary ● Delgocitinib ointment, a topical Janus kinase inhibitor, was effective and well tolerated when applied to Japanese pediatric patients with atopic dermatitis for up to 56 weeks.● Delgocitinib ointment is a promising therapeutic option for atopic dermatitis in children as well as in adults.

Source: Journal of the American Academy of Dermatology - June 9, 2021 Category: Dermatology Authors: Hidemi Nakagawa, Osamu Nemoto, Atsuyuki Igarashi, Hidehisa Saeki, Kenji Kabashima, Manabu Oda, Takeshi Nagata Source Type: research